Satoh et al.indd REVIEW Correspondence: Dr. Hiroyasu Satoh, Department of Pharmacology, Nara Medical University, Kashihara, Nara 634-8521, Japan. Tel: +81-744-29-8831; Fax: +81-744-29-0510; Email: hysat@naramed-u.ac.jp Please note that this article may not be used for commercial purposes. For further information please refer to the copyright statement at http://www.la-press.com/copyright.htm Cardiovascular Pharmacology of Sinomenine: The Mechanical and Electropharmacological Actions Seiichiro Nishida and Hiroyasu Satoh Department of Pharmacology, Division of Traditional Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan Abstract: Sinomenine is one of the alkaloids extracted from Chinese medical plant, Sinomenium acutum Rehder et Wilson. Sinomenine has been used for Rheumatoid arthritis as an anti-infl ammatory and immunomodulative drugs. We have so far been investigated the cardiovascular pharmacological actions of sinomenine. Sinomenine dilated NE (5 µM)-, KCl (60 mM)- and PDB (300 nM)-induced vasoconstrictions. The pretreatment with nicardipine (0.1 µM), staurosporine (30 nM), L-NMMA (100 µM), indomethacin (10 µM) or propranolol signifi cantly attenuated the sinomenine-induced vasorelaxation. Therefore, these results indicate that sinomenine causes the vasorelaxation by the involvement with the inhibitions of Ca2+ current (ICa) and PK-C, β-adrenoceptor stimulation, and the activation of NO and PGI2 syntheses in endothelium. On the other hand, in the ventricular cardiomyocytes of guinea pig, sinomenine inhibits ICa and simultaneously decreases the delayed rectifi er K+ current (IK), resulting in the prolongation of action potential duration. Sinomenine also suppresses the dysrhys- mias induced by triggered activities under the Ca2+ overload condition. Therefore, sinomenine may be expected as one of effective therapeutic drugs for heart failure and dysrhythmias, and may maintain the cardiovascular functions due to modulation of cardiac ionic channels and blood vessels. Keywords: Sinomenine, Vasodilation, Cardioprotective action, Ca2+ channel, Aorta, Cardiomyocytes Introduction Sinomenine (7, 8-didehydro-4-hydroxy-3, 7-dimethoxy-17-methyl-9α,13α,14α-morphinan-6-one) is one of the alkaloids extracted from Chinese herbs, Sinomenium acutum Rehder et Wilson (Li et al. 2004) or Sinomenium acutum var. cinereum (Zhao et al. 2005). In Chinese traditional medicine, Sino- menine acutum, a vine plant, has been used for rheumatic diseases for thousands years (Yamasaki, 1976; Liu et al. 1996). Its main constituent of Sinomenine acutum is sinomenine, which has also used for clinical treatment of Rheumatoid arthritis (RA), due to the anti-infl ammatory and immunomodulative actions (Yamasaki, 1976; Liu et al. 1996). We have already investigated the cardiovascular pharmacological actions of sinomenine. Mokuboito (Mu-Fang-Yi-Tang), a kind of Kampo formulation containing sinomenium acutum, has been used for heart failure (Inaki et al. 2005), which improves heart failure symptom and reduces New York Heart Association (NYHA) class and plasma brain natriuretic peptide (BNP) concentration (Yakubo et al. 2002). Mokuboito consists of Sinomeni Caulis et Rhizoma (rhizome of Sinomenium acutum Rehder et Wilson), Cinnamomi Cortex (bark of Cinnamomum cassia Blume), Ginseng Radix (roots of Panax ginseng C. A. Meyer) and Gypsum Fibrosum. In our recent reports (Satoh, 2005; Nishida and Satoh, 2006; 2007), Mokuboito, Sinomenium acutum and sinomenine might improve chronic heart failure, resulting from the modulation of cardiac and vascular systems. Mokuboito can exert the vasodilating and cardioprotective actions (Satoh, 2005), as discussed in the following parts. In general, the basic treatments of heart failure consist of (1) reducing workload of heart, (2) protec- tion of cardiomyocytes and (3) restriction and control of waters and sodium. In order to reduce both pre- and after-loads, the dilations of arterioles and veins are strongly required in the case of elevated fi lling pressures and reduced cardiac output. As a cardiovascular protective drug, sinomenine might contribute to clinical treatments via modulation of the ionic currents of cardiac cells, and control of the tension of blood vessels. Satoh et al.indd 1 5/14/2007 8:58:41 PM 97Drug Target Insights 2007: 2 97–104 Nishida and Satoh Drug Target Insights 2007: 2 In this review, the cardiovascular pharmaco- logical actions of sinomenine are mainly shown and discussed. Source of Sinomenine Sinomenine is derived from natural plant such as Sinomenium acutum (Li et al. 2004) and Sinome- nium acutum var. cinereum (Zhao et al. 2005). Sinomenium acutum and Sinomenium acutum var. cinereum are widely in a lot of regions of China. Caulis sinomeni is the dried plant stems of Sino- menium acutum and Sinomenium acutum var. cinereum. There is less or no difference in sinome- nine content of Caulis sinomeni between the species and the varieties of growing regions. The variation is found among the samples collected from different parts of plant. The content of sino- menine is dependent on the size (diameter) of stem. The sinomenine content in Sinomenine acutum is 1.63 ± 0.64 (%, w/w) in large (>3 cm) stem, 0.96 ± 0.45 (%, w/w) in 1–3 cm stem, and 0.49 ± 0.16 (%, w/w) in <1 cm stem (Zhao et al. 2005). Pharmacokinetics of Sinomenine The pharmacokinetics and tissue distribution of sinomenine have been studied in rats (Liu et al. 2005). Sinomenine achieves high bioavilability (about 80%) by oral administration of 90 mg/kg. At 45min later, sinomenine is found widely in internal organs such as kidney, liver, lung, spleen, heart, brain and testis. Sinomenine is metabolized and eliminated by kidney and liver. Tmax is 39.5 ± 8.49 min, Cmax is 13.89 ± 4.29 µg/ml, T1/2A phase is 61.28 ± 53.62 min, AUC0-t is 2331.53 ± 1172.77 µg-min/ml, and CL is 42.95 ± 14.4 ml/min per Kg. In clinical studies, oral administration of 80 mg sinomenine is performed for healthy volunteers (Yan et al. 1997). In the pharmacokinetic parame- ters, T1/2α is 1.04 ± 0.491h, T1/2β is 9.397 ± 2.425h, Tmax is 1.04 ± 0.274h, Cmax is 246.6 ± 71.165 ng/ml. Furthermore, AUC is 2651.158 ± 1039.050 ng.h/ml, and CL is 0.033 ± 0.010 ng/ml. Vascular Pharmacology Male Wistar rats (5–10 week-old) were anesthe- tized with ether, and euthanized by exsanguination. The thoracic aorta was quickly removed, and then the isolated aorta was cut into rings of 3-mm in length. All rings were stretched to generate a resting tension of 1.2 g in Krebs solution. After 40 min of resting, norepinephrine (NE) (5 µM) was added to the tissue bath. After the contractile response became steady, the drugs were cumula- tively administrated into the bath solution. The similar methods are described in our previous reports (Nishida and Satoh, 2003; 2006). The aorta ring strip of rat had a strong contrac- tion after an initial application of 5 µM NE. Sino- menine (0.1 to 100 µM) applications potently relaxed the contraction induced by NE in a concen- tration-dependent manner (Nishida and Satoh, 2006). The relaxation was produced at the concen- trations of over 0.3 µM sinomenine, and at 100 µM decreased the contractions by 68.8 ± 5.1% (n = 6, p < 0.001). PDB (300 nM) and KCl (60 mM) also caused strong contractions. Sinomenine dilated both PDB- and KCl-induced contractions in a concentration-dependent manner; at 100 µM by 49.9 ± 9.8% (n = 6, p < 0.001) and 86.9 ± 8.5% (n = 6, p < 0.001), respectively (Fig. 1). Further- more, the relaxation of sinomenine (0.1 to 100 µM) was attenuated signifi cantly by the pretreatment with nicardipine (Fig. 2). At 100 µM the relaxation decreased from 68.8 ± 5.1% (n = 6) to 35.5 ± 6.9% (n = 5, p < 0.001). Since PK-C inhibition may be related to sinomenine-induced vasorelaxation, the pretreatment with staurosporine (30 nM) for 30 min was carried out (Satoh, 1996; Nishida and Satoh, 2004). Staurosporine attenuated the sino- menine-induced vasorelaxation; at 100 µM from 68.8 ± 5.1% (n = 6) to 49.5 ± 7.7% (n = 5, p < 0.001) (Fig. 2). In addition, propranolol (0.3 µM) also signifi cantly attenuated the sinomenine- induced relaxation. The vasorelaxation at 100 µM sinomenine was attenuated to 45.2 ± 4.2% (n = 5, p < 0.01). Therefore, the modulation of both Ca2+ channel and PK-C is largely contributed to sinomenine- induced actions, and sinomenine also vasodilates mediated through β-adrenoceptor stimulation of aortic smooth muscle cells. For involvement with endothelium-dependent relaxation via NO activation, a pretreatment with 100 µM L-NMMA (a non-selective NO synthesis inhibitor) was carried out (Nishida and Satoh, 2003; 2007). Under the conditions, the vasorelax- ation induced by sinomenine was attenuated from 68.8 ± 5.1% (n = 6) to 25.3 ± 2.3% (n = 5, p < 0.01) (Fig. 2). The attenuation was supported by the results using the aorta with removal of endothe- lium; at 100 µM sinomenine by 53.7 ± 1.8% (n = 5, p < 0.01). Indomethacin (10 µM), as an Satoh et al.indd 2 5/14/2007 8:59:09 PM 98 Cardiovascular pharmacology of sinomenine Drug Target Insights 2007: 2 inhibitor of prostanoid production, also strongly reduced the vasorelaxation induced by 100 µM sinomenine to 37.1 ± 9.3% (n = 5, p < 0.001). Thus, both L-NMMA and indomethacin affected the sinomenine-induced relaxation significantly. Therefore, sinomenine possesses the pharmaco- logical characteristics for modulation of NO synthesis and PG production, as well as the inhibi- tions of Ca2+ channel and PK-C and the stimulation of β-adrenoceptor. The possible mechanisms for the vasodilating actions of sinomenine are summarized in Fig. 3. Cardiac Electropharmacology Cardiac cells were taken from the ventricle muscles of guinea pig hearts, using methods similar to those described previously (Satoh, 2003, 2005). Current- clamp and whole-cell voltage-clamp were performed using an Axopatch patch-clamp amplifi er (Axon Instruments, Burlingame, C.A, U.S.A.) and standard techniques. Current-clamp experiments were carried out to examine the modulation of the action potential confi guration in guinea pig ventricular muscles (Fig. 4A) (Satoh, 2005). Sinomenine at 300 µM and 1 mM increased the 75% repolarization of action potential duration (APD75) by 24.9 ± 3.5% (n = 6, p < 0.05) and by 43.7 ± 3.3% (n = 6, p < 0.001), respectively. Sinomenine at 1 mM decreased the amplitude (APA), but not signifi - cantly (0.9 ± 2.1%, n = 5). The resting potential was not affected. The modulation of L-type Ca2+ current (ICa) was investigated. Test pulses were applied to 0 mV from a holding potential of –30 mV. The average capac- itance was 84.1 ± 2.4 pF (n = 23). At 1 mM sino- menine inhibited the ICa at 0 mV by 18.2 ± 2.1% (n = 6, p < 0.05). At 1 mM, the delayed rectifi er K+ currents (IK) at 60 mV was inhibited by 16.2 ± 2.6% (n = 6, p < 0.05) (Fig. 4B), and the inwardly rectifying K+ current (IK1) at -120 mV by 47.2 ± 3.8% (n = 6, p < 0.01). s inome nine 0 10 20 30 40 50 60 70 80 90 100 0.1 0.3 1 3 10 30 100 R el ax at io nn (% ) NE P DB KC μ M Figure 1. Concentration-dependent relaxation of sinomenine on NE-, PDB- and KCl-induced vasorelaxations. Symbols used are sinomenine in pretreatments with NE (open circles, n = 6), PDB (triangles, n = 6) and KCl (squares, n = 6). Values (%) represent mean ± S.E.M. *: P < 0.05, **: P < 0.01, ***: P < 0.001, with respect to control value. Satoh et al.indd 3 5/14/2007 8:59:10 PM 99 Nishida and Satoh Drug Target Insights 2007: 2 In multicellular preparations, the modulation of action potential confi guration by sinomenine was also examined (Satoh, 2005). The prepara- tions were stimulated at 1 Hz. Sinomenine (100 µM to 1 mM) had inhibitory effects on the action potentials, and tended to increase the action potential durations (APD); at 1 mM, by 4.1± 1.6% (n = 6) in APD50 and by 4.5 ± 1.4% (n = 6) in APD90 (but not signifi cantly). The maximum rate of depolarization (Vmax) was also inhibited by 20.0 ± 2.4% (n = 6, p < 0.05) at 300 µM and by 32.1 ± 3.3% (n = 6, p < 0.05) at 1 mM of sinomenine. In high extracellular Ca2+ ([Ca2+]o) solution (5.4 mM) to cause cellular Ca2+ overload, abnormal action potentials occurred irregularly, in spite of constant stimulation (1 Hz) (Satoh, 2005). Application of 300 µM sinomenine suppressed and abolished the abnormal action potentials (dysrhyth- mias) (Fig. 5). The changes in the action potential confi gura- tions and the modulation of the ionic channel currents on the membrane of cardiomyocyte by sinomenine are summarized in Fig. 6. Immunomodulative Action Sinomenium acutum has been used for treatment for various rheumatic diseases as a Chinese traditional medicine (Yamasaki, 1976; Liu et al. 1996). In basic pharmacological studies of Sino- menium acutum, the inhibitory actions on some enzymes relating to infl ammation have been shown (Li et al. 2003). One of most famous pharmacological actions of sinomenine is an immunomodulative effect. Sinomenine is also clinically used for RA treat- ment (Yamasaki, 1976; Liu et al. 1996). A lot of reports concerning about not only an anti-rheu- matic effect, but also anti-inflammatory and immunomodulative effects have already been shown. As anti-rheumatic direct effects, it has been reported that sinomenine reduces infl amma- tory parameters and attenuates proliferation of Figure 2. Modulation by several inhibitors of the relaxation induced by sinomenine. Symbols used are in the absence (open circles, n = 6), in the presence of 100 µM L-NMMA (open triangles, n = 5), 10 µM indomethacin (open squares, n = 5), 0.1 µM nicardipine (closed circles, n = 5), 0.3 µM propranolol (closed triangles, n = 5), and 30 nM staurosporine (closed squares, n = 5). Values (%) represent mean ± S.E.M. *: P < 0.05, **: P < 0.01, ***: P < 0.001, with respect to control value. Satoh et al.indd 4 5/14/2007 8:59:10 PM 100 Cardiovascular pharmacology of sinomenine Drug Target Insights 2007: 2 synovial fibroblasts in rat adjuvant arthritis models (Liu et al. 1996). The anti-infl ammatory and immunomodulative actions of sinomenine are responsible for various mechanisms via complex modulation of leukocytes and cytokine. Sinomenine reduces the production of prosta- grandin (PG) E2 and NO from macrophage (Liu et al. 1994a). Also, sinomenine possesses anti-proliferative effects on lymphocytes (Liu et al. 1994b), contributing to anti-infl ammatory and anti-rheumatic effects. In addition, sinome- nine depressed mRNA expression of tumor necrosis factor (TNF)-α and interleukin (IL)-β of peritoneal macrophages (Wang et al. 2005). Therefore, sinomenine may act as an anti-rheu- matic drug through the anti-infl ammatory effects on lymphocytes and cytokine. Sinomenine inhib- ited bFGF-induced angiogenesis in vitro and in vivo (Kok et al. 2005). Sinomenine also attenuates transmigration of granulocyte. The inhibition of leukocytes migration across the vessel wall and anti-angiogeneic effect of sinomenine may also contribute to therapeutic effects for RA. Immu- nomodulative actions have been studied as the other aspect of sinomenine concerning about the cardiac transplantation model. It has been reported that acute and chronic cardiac allograft ejections are blocked by the immunomodulatory effects of sinomenine (Mark et al. 2003). Conclusion Endothelium-dependent and -independent relaxations We have been demonstrated that sinomenine possesses strong vasodilating actions by multiple mechanisms (Nishida and Satoh, 2006). The summarized mechanisms of sinomenine-induced vasorelaxation are shown in Fig. 3. Sinomenine possesses endothelium-dependent vasorelaxation via NO and PGI2 releasing from endothelium. NOS activation and PGI2 release are elicited by an increase in the intracellular Ca2+ concentration ([Ca2+]i) in endothelium cells (Busse et al. 1998; Quignard et al. 1999). The mechanisms for the endothelium-dependent relaxations are not yet unclear. However, sinomenine might increase [Ca2+]i in endothelium cells and then, activates Figure 3. Summary of the multiple mechanisms induced by sinomenine. Sinomenine produces the vasorelaxation via NO and PGI2 releas- ings from endothelium. Also, sinomenine causes the vasorelaxation via modulation of Ca2+ channels and PK-C activity in smooth muscle cells. In addition, β-adrenoceptor stimulation is caused. NOS: nitric oxide synthetase, PK-C: protein kinase C, PGI2 : prostaglandin I2. Satoh et al.indd 5 5/14/2007 8:59:10 PM 101 Nishida and Satoh Drug Target Insights 2007: 2 NOS activity and PGI2 releasing, as reported previ- ously (Nishida and Satoh, 2003). Sinomenine causes the vasorelaxation via modula- tion of Ca2+ channels and PK-C activity in vascular smooth muscle cells. In vascular muscle cells, the contraction systems and the ion channels are regu- lated through the intracellular signal conditions (Satoh and Sperelakis, 1991, 1995; Satoh, 1996). Therefore, sinomenine might modulate the contrac- tion systems, Ca2+ and Na+ channels, delayed rectifi er K+ channels, and Ca2+-activated K+ (KCa) channel, accompanied with the activation of PK-C (Nishida and Satoh, 2007). Also, sinomenine possesses β-adrenoceptor stimulating action to inhibit the aortic constriction. Clinically possibility of cardiovascular pharmacological effects Sinomenine is included in Sinomenine acutum of Mokuboito. Mokuboito is traditionally used for dyspnea and edema (Shuji et al. 2002). Therefore, sinomenine may be expected as one of the thera- peutic agents for heart failure. Most recently, Satoh (2005) has demonstrated that sinomenine effec- tively modulates cardiac ionic channels. Sinome- nine inhibits ICa , and simultaneously produces the IK decerease in cardiomyocytes which results in the APD prolongation. Modulation of Ca2+ channel induced by sinomenine is similarly exerted in vascular smooth muscle cells. In addition, sinome- nine possesses the regulatory actions for dysrhyth- mias under Ca2+ overload conditions. It has been well known that under the ischemia and heart failure, the cellular Ca2+ overload of heart muscles elicits some arrhythmias and dysfunctions (Satoh, 2001; 2003). The regulation of Ca2+ infl ux may modulate Ca2+ overload in cardiomyocytes and produces protective actions for Ca2+-overloaded myocardial cells (Satoh and Spererakis, 1998). Therefore, sinomenine might restrain the cell damages of heart muscles via modulation of [Ca2+]i, and as a result, exert a cardioprotective action. Cardiopotective action of sinomenine on rat acute myocardial ischemia has also been demon- strated. Reperfusion injury is induced by ligating the rat left coronary artery for 15 min and reopening. Sinomenine can inhibit the incidence of B A Figure 4. Modulation by sinomenine on the action potentials in guinea pig ventricular cardiomyocytes. A: Concentration-dependent chang- es in the action potential confi guration by sinomenine. Short lines at the left of action potential recordings represent zero mV level. B: The percentage inhibitions by sinomenine of cardiac ionic currents. Vertical bars represent mean ± SEM. Figure 5. Antiarrhythmic actions of sinomenine in guinea pig papillary muscles. Sinomenine abolishes the abnormal action potentials in high Ca2+ concentration (5.4 mM). Dots above the action potential recordings are represented the regular rhythms induced by 1 Hz stimulation. The horizontal line indicates zero mV. Satoh et al.indd 6 5/14/2007 8:59:10 PM 102 Cardiovascular pharmacology of sinomenine Drug Target Insights 2007: 2 arrhythmias and reduce intracellular Ca2+ concen- tration (Xie et al. 1993), well consistent with our results. Sinomenine has multiple vasodilating mechanisms. The vasodilating agent is one of the great useful tools for heart failure and regulates pre- and after- loads of cardiovascular systems. Therefore, sinomenine-induced vasodilating actions may improve cardiac functions via the regulation of both pre- and after-loads under heart failure. In summary, sinomenine caused a concentration- dependent vasorelaxation on NE-, KCl- and PDB-induced contractions, and sinomenine- induced vasorelaxation is attenuated by the pretreatments with L-NMMA, indomethacin, staurosporine, nicardipine and propranolol. In electropharmacological mechanisms, sinomenine inhibits the ICa and the IK in cardiomyocytes which results in the APD prolongation. In addition, sinomenine depressed the dysrhysmias induced by triggered activities under the Ca2+ overload. Finally, sinomenine also possesses the anti- infl ammatory and immunomodulative actions. In future, therefore, sinomenine as a cardiopro- tective drug may be expected to the respectable effectiveness for heart failure, mediated through the modulation of cardiac ion channels (including the regulation for dysrhythmias) and blood vessels. Further experiments need to elucidate more in detail mechanisms of sinomenine. Acknowledgements The authors wish to express thanks for the supply of Mokuboito and Sinomenium acutum extracts (Tsumura Co.). This work was in part supported by the research fund of Japan Kampo Medicine Manufactures Association. References Busse, R., Fichter, H., Luckhoff, A. et al. 1998. Hyperpolarizaion and increased free calcium in acethylcholine-stimulated endothelium cells. Am. J. physiol., 255:H965–9. Inaki, K. 2005. Diseases and Kampo. In Sato, Y., Hanawa, T., Arai, M., Cyong, J., Fukuzawa, M., Mitani, K., Ogihara, Y., Sakiyama, T., Shimada, Y., Toriizuka, K., Ymamada, T. ed. Introduction to Kampo. Elsevier Japan. p125. Kok, T.W., Yue, P.Y., MaK, N.K. et al. 2005. The anti-angiogenic effect of sinomenine. Angiogenesis, 8(1):3–12. Kubota, Y., Tanaka, T. and Umegaki, K. 2001. Ginkgo biloba extract-induced relaxation of rat aorta is associated with increase in endothelial in- tracellular calcium level. Life Sci., 69:2327–36. Li, R.W., David, Lin, G., Myers, S.P. et al. 2003. Anti-inflammatory activity of Chinese medical vine plants. J. Ethnopharmacol. 85(1):61–7. Li, Y., Cui, S., Cheng, Y. et al. 2004. Application of nonaqueous capillary electrophoresis for quantitative analysis of quinolizidine alkaloids in Chinese herbs. Anal. Chim. Acta., 508:17–22. Liu, L., Riese, J., Resch, K. et al. 1994 (a). Impairment of macropharge eicosanoids and nitric oxide production by alkaloid from Sinome- nium acutum. Arzneimittelforschung, 44:1223–26. Liu, L., Resch, K., and Kaever, V. 1994 (b). Inhibition of lymphocyte pro- liferation by the anti-arthritc drug of sinomenine. Int. J. Immuno- pharmacol., 16(8):685–91. Liu, L., Buchner, E., Beitze, D. et al. 1996. Amelioration of rat experimen- tal arthritides by treatment with the alkaloid sinomenine. Int. J. Im- munopharmacol., 18(10):529–43. Liu, Z.Q., Chan, K., Zhou, H. et al. 2005. The pharmacokinetics and tissues distribution of sinomenine in rats and its protein binding ability in vitro. Life Sci., 77(25):3197–209. Lopez-Jaramillo, P., Gonzalez, M.C., Palmer, R.M. et al. 1990. The crucial role of physiological Ca2+ concentrations in the production of endothelial nitric oxide and the control of vascular tone. Br. J. Phar- macol., 101(2):489–93. Mark, W., Schneeberger, S., Seiler, R. et al. 2003. Sinomenine blocks tissue remodeling in a rat model of chronic cardiac allograft rejection. Transplantation, 15:940–5. Nishida, S., and Satoh, H. 2003. Mechanisms for the vasodilations induced by Ginkgo biloba extract and its main constituent, bilobalide, in rat aorta. Life Sci., 72:2659–67. Nishida, S., and Satoh, H. 2004. Comparative vasodilating actions among terpenoids and fl avonoids contained in Ginkgo biloba extract. Cli- nica Chimica Acta., 339:129–33. Nishida, S., and Satoh, H. 2006. In vitro pharmacological actions of sino- menine on the smooth muscle and endothelial cell activity in rat aorta. Life Sci., 79:1203–06. Nishida, S., and Satoh, H. 2007. Vascular pharmacology of Mokuboito (Mu-Fang-Yi-Tang) and its constituents on the smooth muscle and the endothelium in rat aorta. eCAM (in press). Quignard, J.F., Feleton, M., Thollon, C. et al. 1999. Pottasium ions and endothelium-derived hyperpolarizing factor in guinea-pig carotid and porcine coronary arteries. Br. J. Pharmacol., 127:27–37. Figure 6. Shame for the changes in cardiac ionic channels induced by sinomenine. Superimposed action potentials are in control (solid line) and in sinomenine (dash line). INa: the Na + channel, ICa: the Ca 2+ channel, IK: the delayed rectifi er K +channel, IK1: the inwardly rectifying K+channel. Satoh et al.indd 7 5/14/2007 8:59:10 PM 103 Nishida and Satoh Drug Target Insights 2007: 2 Satoh, H. 1996. Modulation of Ca2+-activated K+ current by isoprenaline, carbachol, and phorbol ester in cultured (and fresh) rat aortic vascu- lar smooth muscle cells. Gen. Pharmacol., 27:319–24. Satoh, H. 2001. [Ca2+]i- dependent actions of taurine in spontaneously beat- ing rabbit sino-atrial nodal cells. Eur. J. Pharmacol., 424:19–25. Satoh, H. 2003. Effects of Ginkgo biloba extract and bilobalide, a main constituent, on the ionic currents in guinea pig ventricular cardio- myocytes. Arzneimittelforschung, 53:407–13. Satoh, H. 2005. Electropharmacology of sinomeni caulis et rhizome and its constituents in cardiomyocytes. Am. J. Chin. Med., 33:967–79. Satoh, H., and Sperelakis, N. 1991. Calcium and potassium currents in cultured rat aortic vascular smooth muscle cell lines. In Sperelakis N ed. Ion Channels of Vascular Smooth Muscle Cells and Endothe- lial Cells. Academic Press, New York: p55–63. Satoh, H. and Sperelakis, N. 1995. Modulation of L-type Ca2+ current by isoprenaline, carbachol and phorbol ester in cultured rat aortic vas- cular smooth muscle (A7r5) cells. Gen. Pharmacol., 26: 369–79. Satoh, H. and Sperelakis, N. 1998. Review of some actions of taurine on ion channels of cardiac muscle cells and others. Gen. Pharmacol., 30:451–63. Shuji, Y., Kinoshita, Y., Arakawa, Y. et al. 2002. Clinical evaluation of Moku-boi-to(Mu-Fang-Yi-Tang): a Japanese and Chinese tradi- tional medicine for heart failure. J. Trad. Med., 19:159–63. Wang, Y., Fang, Y., Huang, W. et al. 2005. Effect of sinomenine on cytokine expression of macrophages and synoviocytes in adjuvant arthritis rats. J. Ethopharmacol., 98:37–43. Yamasaki, H. 1976. Pharmacology of sinomenine, an anti-rheumatic alka- loids from sinomenine acutum. Acta Med Okayama, 30:1–20. Xie, S.X., and Jin, Q.Q. 1993. Prevention of sinomenine on isolated rat myocardial reperfusion injury. Zhongguo Yao Li Xue Bao, Suppl: S12–5. Yan, X.H., Li, H.D., Peng, W.X. et al. 1997. Determination of sinomenine HCl in serum and urine by HPLC and its pharmacokinetics in normal volunteers. Yao Xue Xue Bao, 32(8):620–4. Zhao, Z.Z., Liang, Z.T., Zhou, H. et al. 2005. Quantifi cation of sinomenine in caulis sinomenii collected from different growing regions and wholesale herbal markets by a modifi ed HPLC method. Biol. Pharm. Bull., 28(1):105–9. Satoh et al.indd 8 5/14/2007 8:59:11 PM 104 << /ASCII85EncodePages false /AllowTransparency false /AutoPositionEPSFiles true /AutoRotatePages /None /Binding /Left /CalGrayProfile (Dot Gain 20%) /CalRGBProfile (sRGB IEC61966-2.1) /CalCMYKProfile (U.S. Web Coated \050SWOP\051 v2) /sRGBProfile (sRGB IEC61966-2.1) /CannotEmbedFontPolicy /Error /CompatibilityLevel 1.4 /CompressObjects /Tags /CompressPages true /ConvertImagesToIndexed true /PassThroughJPEGImages true /CreateJDFFile false /CreateJobTicket false /DefaultRenderingIntent /Default /DetectBlends true /ColorConversionStrategy /LeaveColorUnchanged /DoThumbnails false /EmbedAllFonts true /EmbedJobOptions true /DSCReportingLevel 0 /EmitDSCWarnings false /EndPage -1 /ImageMemory 1048576 /LockDistillerParams false /MaxSubsetPct 100 /Optimize true /OPM 1 /ParseDSCComments true /ParseDSCCommentsForDocInfo true /PreserveCopyPage true /PreserveEPSInfo true /PreserveHalftoneInfo false /PreserveOPIComments false /PreserveOverprintSettings true /StartPage 1 /SubsetFonts true /TransferFunctionInfo /Apply /UCRandBGInfo /Preserve /UsePrologue false /ColorSettingsFile () /AlwaysEmbed [ true ] /NeverEmbed [ true ] /AntiAliasColorImages false /DownsampleColorImages true /ColorImageDownsampleType /Bicubic /ColorImageResolution 300 /ColorImageDepth -1 /ColorImageDownsampleThreshold 1.50000 /EncodeColorImages true /ColorImageFilter /DCTEncode /AutoFilterColorImages true /ColorImageAutoFilterStrategy /JPEG /ColorACSImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /ColorImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /JPEG2000ColorACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000ColorImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasGrayImages false /DownsampleGrayImages true /GrayImageDownsampleType /Bicubic /GrayImageResolution 300 /GrayImageDepth -1 /GrayImageDownsampleThreshold 1.50000 /EncodeGrayImages true /GrayImageFilter /DCTEncode /AutoFilterGrayImages true /GrayImageAutoFilterStrategy /JPEG /GrayACSImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /GrayImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /JPEG2000GrayACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000GrayImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasMonoImages false /DownsampleMonoImages true /MonoImageDownsampleType /Bicubic /MonoImageResolution 1200 /MonoImageDepth -1 /MonoImageDownsampleThreshold 1.50000 /EncodeMonoImages true /MonoImageFilter /CCITTFaxEncode /MonoImageDict << /K -1 >> /AllowPSXObjects false /PDFX1aCheck false /PDFX3Check false /PDFXCompliantPDFOnly false /PDFXNoTrimBoxError true /PDFXTrimBoxToMediaBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXSetBleedBoxToMediaBox true /PDFXBleedBoxToTrimBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXOutputIntentProfile () /PDFXOutputCondition () /PDFXRegistryName (http://www.color.org) /PDFXTrapped /Unknown /Description << /ENU (Use these settings to create PDF documents with higher image resolution for high quality pre-press printing. The PDF documents can be opened with Acrobat and Reader 5.0 and later. These settings require font embedding.) /JPN /FRA /DEU /PTB /DAN /NLD /ESP /SUO /ITA /NOR /SVE >> >> setdistillerparams << /HWResolution [2400 2400] /PageSize [612.000 792.000] >> setpagedevice